Fate Therapeutics, Inc
Price
FilingsNewest: 8-K, Other eventsSep 28 →InsidersNo open-market buys. 2 insiders sold $119,305, 0 of 4 sales on a 10b5-1 plan.→HoldersRedmile 11.0%BlackRock 6.3%Vanguard Portfolio 3.9%→PeersClosest companies: IPSC, CABA, TCRX→
From the filings
Figures
- Revenue
- $6.5Mlast 12 months
- Net income
- −$126.0Mlast 12 months
- Operating cash flow
- −$103.1Mlast 12 months
- Cash and equivalents
- $32.4Mat the last balance sheet
- Shares outstanding
- 116.7M shareson issue